A Phoenix-based biotech company is hoping to start human clinical trials to test whether an engineered virus can kill off cancer cells, while not hurting healthy ones.
OncoMyx was formed with that goal in mind and recently finalized a licensing deal with Arizona State University's tech transfer organization.
To talk more about the science behind this, The Show spoke with Grant McFadden. He’s a professor at ASU and director of the Biodesign Institute’s Center for Immunotherapy, Vaccines and Virotherapy.
